Top 10 Challenges in Cancer Immunotherapy von Hegde, Priti S., Chen, Daniel S.

Volltext

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition von Hegde, Priti S, Karanikas, Vaios, Evers, Stefan

Volltext

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics von Hegde, Priti S., Wallin, Jeffrey J., Mancao, Christoph

Volltext

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade von Motzer, Robert J., Banchereau, Romain, Hamidi, Habib, Powles, Thomas, McDermott, David, Atkins, Michael B., Escudier, Bernard, Liu, Li-Fen, Leng, Ning, Abbas, Alexander R., Fan, Jinzhen, Koeppen, Hartmut, Lin, Jennifer, Carroll, Susheela, Hashimoto, Kenji, Mariathasan, Sanjeev, Green, Marjorie, Tayama, Darren, Hegde, Priti S., Schiff, Christina, Huseni, Mahrukh A., Rini, Brian

Volltext

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients von Herbst, Roy S., Soria, Jean-Charles, Kowanetz, Marcin, Fine, Gregg D., Hamid, Omid, Gordon, Michael S., Sosman, Jeffery A., McDermott, David F., Powderly, John D., Gettinger, Scott N., Kohrt, Holbrook E. K., Horn, Leora, Lawrence, Donald P., Rost, Sandra, Leabman, Maya, Xiao, Yuanyuan, Mokatrin, Ahmad, Koeppen, Hartmut, Hegde, Priti S., Mellman, Ira, Chen, Daniel S., Hodi, F. Stephen

Volltext

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study von McDermott, David F, Sosman, Jeffrey A, Sznol, Mario, Massard, Christophe, Gordon, Michael S, Hamid, Omid, Powderly, John D, Infante, Jeffrey R, Fassò, Marcella, Wang, Yan V, Zou, Wei, Hegde, Priti S, Fine, Gregg D, Powles, Thomas

Volltext

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma von Wallin, Jeffrey J., Bendell, Johanna C., Funke, Roel, Sznol, Mario, Korski, Konstanty, Jones, Suzanne, Hernandez, Genevive, Mier, James, He, Xian, Hodi, F. Stephen, Denker, Mitchell, Leveque, Vincent, Cañamero, Marta, Babitski, Galina, Koeppen, Hartmut, Ziai, James, Sharma, Neeraj, Gaire, Fabien, Chen, Daniel S., Waterkamp, Daniel, Hegde, Priti S., McDermott, David F.

Volltext

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab von Gandara, David R., Paul, Sarah M., Kowanetz, Marcin, Schleifman, Erica, Zou, Wei, Li, Yan, Rittmeyer, Achim, Fehrenbacher, Louis, Otto, Geoff, Malboeuf, Christine, Lieber, Daniel S., Lipson, Doron, Silterra, Jacob, Amler, Lukas, Riehl, Todd, Cummings, Craig A., Hegde, Priti S., Sandler, Alan, Ballinger, Marcus, Fabrizio, David, Mok, Tony, Shames, David S.

Volltext

Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer von Desbois, Mélanie, Udyavar, Akshata R., Ryner, Lisa, Kozlowski, Cleopatra, Guan, Yinghui, Dürrbaum, Milena, Lu, Shan, Fortin, Jean-Philippe, Koeppen, Hartmut, Ziai, James, Chang, Ching-Wei, Keerthivasan, Shilpa, Plante, Marie, Bourgon, Richard, Bais, Carlos, Hegde, Priti, Daemen, Anneleen, Turley, Shannon, Wang, Yulei

Volltext

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer von Powles, Thomas, Eder, Joseph Paul, Fine, Gregg D., Braiteh, Fadi S., Loriot, Yohann, Cruz, Cristina, Bellmunt, Joaquim, Burris, Howard A., Petrylak, Daniel P., Teng, Siew-leng, Shen, Xiaodong, Boyd, Zachary, Hegde, Priti S., Chen, Daniel S., Vogelzang, Nicholas J.

Volltext

Molecular determinants of response to PD-L1 blockade across tumor types von Banchereau, Romain, Leng, Ning, Zill, Oliver, Sokol, Ethan, Liu, Gengbo, Pavlick, Dean, Maund, Sophia, Liu, Li-Fen, Kadel, Edward, Baldwin, Nicole, Jhunjhunwala, Suchit, Nickles, Dorothee, Assaf, Zoe June, Bower, Daniel, Patil, Namrata, McCleland, Mark, Shames, David, Molinero, Luciana, Huseni, Mahrukh, Sanjabi, Shomyseh, Cummings, Craig, Mellman, Ira, Mariathasan, Sanjeev, Hegde, Priti, Powles, Thomas

Volltext

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised c... von Powles, Thomas, Durán, Ignacio, van der Heijden, Michiel S, Loriot, Yohann, Vogelzang, Nicholas J, De Giorgi, Ugo, Oudard, Stéphane, Retz, Margitta M, Castellano, Daniel, Bamias, Aristotelis, Fléchon, Aude, Gravis, Gwenaëlle, Hussain, Syed, Takano, Toshimi, Leng, Ning, Kadel, Edward E, Banchereau, Romain, Hegde, Priti S, Mariathasan, Sanjeev, Cui, Na, Shen, Xiaodong, Derleth, Christina L, Green, Marjorie C, Ravaud, Alain

Volltext

Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin von Woodhouse, Ryan, Li, Meijuan, Hughes, Jason, Delfosse, David, Skoletsky, Joel, Ma, Pei, Meng, Wei, Dewal, Ninad, Milbury, Coren, Clark, Travis, Donahue, Amy, Stover, Dan, Kennedy, Mark, Dacpano-Komansky, Jennifer, Burns, Christine, Vietz, Christine, Alexander, Brian, Hegde, Priti, Dennis, Lucas

Volltext

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response von Montesion, Meagan, Murugesan, Karthikeyan, Jin, Dexter X, Sharaf, Radwa, Sanchez, Nora, Guria, Ameet, Minker, Max, Li, Gerald, Fisher, Virginia, Sokol, Ethan S, Pavlick, Dean C, Moore, Jay A, Braly, Alan, Singal, Gaurav, Fabrizio, David, Comment, Leah A, Rizvi, Naiyer A, Alexander, Brian M, Frampton, Garrett M, Hegde, Priti S, Albacker, Lee A

Volltext

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells von Mariathasan, Sanjeev, Turley, Shannon J., Nickles, Dorothee, Castiglioni, Alessandra, Yuen, Kobe, Wang, Yulei, Kadel III, Edward E., Koeppen, Hartmut, Astarita, Jillian L., Cubas, Rafael, Jhunjhunwala, Suchit, Banchereau, Romain, Yang, Yagai, Guan, Yinghui, Chalouni, Cecile, Ziai, James, Şenbabaoğlu, Yasin, Santoro, Stephen, Sheinson, Daniel, Hung, Jeffrey, Giltnane, Jennifer M., Pierce, Andrew A., Mesh, Kathryn, Lianoglou, Steve, Riegler, Johannes, Carano, Richard A. D., Eriksson, Pontus, Höglund, Mattias, Somarriba, Loan, Halligan, Daniel L., van der Heijden, Michiel S., Loriot, Yohann, Rosenberg, Jonathan E., Fong, Lawrence, Mellman, Ira, Chen, Daniel S., Green, Marjorie, Derleth, Christina, Fine, Gregg D., Hegde, Priti S., Bourgon, Richard, Powles, Thomas

Volltext

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient S... von Trabucco, Sally E., Gowen, Kyle, Maund, Sophia L., Sanford, Eric, Fabrizio, David A., Hall, Michael J., Yakirevich, Evgeny, Gregg, Jeffrey P., Stephens, Phil J., Frampton, Garrett M., Hegde, Priti S., Miller, Vincent A., Ross, Jeffrey S., Hartmaier, Ryan J., Huang, Shih-Min A., Sun, James X.

Volltext

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma von McDermott, David F., Huseni, Mahrukh A., Atkins, Michael B., Motzer, Robert J., Rini, Brian I., Escudier, Bernard, Fong, Lawrence, Joseph, Richard W., Pal, Sumanta K., Reeves, James A., Sznol, Mario, Hainsworth, John, Rathmell, W. Kimryn, Stadler, Walter M., Hutson, Thomas, Gore, Martin E., Ravaud, Alain, Bracarda, Sergio, Suárez, Cristina, Danielli, Riccardo, Gruenwald, Viktor, Choueiri, Toni K., Nickles, Dorothee, Jhunjhunwala, Suchit, Piault-Louis, Elisabeth, Thobhani, Alpa, Qiu, Jiaheng, Chen, Daniel S., Hegde, Priti S., Schiff, Christina, Fine, Gregg D., Powles, Thomas

Volltext

Balancing speed, science and regulatory requirements in oncology drug development von Snyder, Alexandra, De Alwis, Dinesh, Goonewardene, Asthika, Hegde, Priti S.

Volltext

A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases von Huang, Richard S.P., Haberberger, James, Severson, Eric, Duncan, Daniel L., Hemmerich, Amanda, Edgerly, Claire, Ferguson, Naomi Lynn, Williams, Erik, Elvin, Julia, Vergilio, Jo-Anne, Killian, Jonathan Keith, Lin, Douglas I., Tse, Julie, Hiemenz, Matthew, Owens, Clarence, Danziger, Natalie, Hegde, Priti S., Venstrom, Jeffrey, Alexander, Brian, Ross, Jeffrey S., Ramkissoon, Shakti H.

Volltext

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade von Yuen, Kobe C., Liu, Li-Fen, Gupta, Vinita, Madireddi, Shravan, Keerthivasan, Shilpa, Li, Congfen, Rishipathak, Deepali, Williams, Patrick, Kadel, Edward E., Koeppen, Hartmut, Chen, Ying-Jiun, Modrusan, Zora, Grogan, Jane L., Banchereau, Romain, Leng, Ning, Thastrom, AnnChristine, Shen, Xiadong, Hashimoto, Kenji, Tayama, Darren, van der Heijden, Michiel S., Rosenberg, Jonathan E., McDermott, David F., Powles, Thomas, Hegde, Priti S., Huseni, Mahrukh A., Mariathasan, Sanjeev

Volltext